BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2546667)

  • 21. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
    Knecht W; Henseling J; Löffler M
    Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological effects of the dihydroorotate dehydrogenase inhibitor polyporic acid, a toxic constituent of the mushroom Hapalopilus rutilans, in rats and humans.
    Kraft J; Bauer S; Keilhoff G; Miersch J; Wend D; Riemann D; Hirschelmann R; Holzhausen HJ; Langner J
    Arch Toxicol; 1998 Nov; 72(11):711-21. PubMed ID: 9879809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
    McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
    Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors.
    DeFrees SA; Sawick DP; Cunningham B; Heinstein PF; Morré DJ; Cassady JM
    Biochem Pharmacol; 1988 Oct; 37(20):3807-16. PubMed ID: 2847745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis.
    Kobayashi K; Nakashima A; Nagata H; Nakajima H; Yamaguchi K; Sato S; Miki I
    Inflamm Res; 2001 Jan; 50(1):24-31. PubMed ID: 11235018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program.
    Cleaveland ES; Monks A; Vaigro-Wolff A; Zaharevitz DW; Paull K; Ardalan K; Cooney DA; Ford H
    Biochem Pharmacol; 1995 Mar; 49(7):947-54. PubMed ID: 7741767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
    Schwartsmann G; Dodion P; Vermorken JB; ten Bokkel Huinink WW; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh WJ; van Hennik MB
    Cancer Chemother Pharmacol; 1990; 25(5):345-51. PubMed ID: 2306795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
    Chen SF; Ruben RL; Dexter DL
    Cancer Res; 1986 Oct; 46(10):5014-9. PubMed ID: 3019518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydroorotase and dihydroorotate dehydrogenase.
    Chen JJ; Jones ME
    J Biol Chem; 1979 Jun; 254(11):4908-14. PubMed ID: 35542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular pharmacology of DUP-785, a new anticancer agent.
    Anderson LW; Strong JM; Cysyk RL
    Cancer Commun; 1989; 1(6):381-7. PubMed ID: 2562006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
    He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
    Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
    Bruneau JM; Yea CM; Spinella-Jaegle S; Fudali C; Woodward K; Robson PA; Sautès C; Westwood R; Kuo EA; Williamson RA; Ruuth E
    Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of the novel anticancer drug candidate Brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts.
    Shen HS; Chen SF; Behrens DL; Whitney CC; Dexter DL; Forbes M
    Cancer Chemother Pharmacol; 1988; 22(3):183-6. PubMed ID: 3409452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
    Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
    Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
    Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
    Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
    Hurt DE; Sutton AE; Clardy J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical genetic analysis of pyrimidine biosynthesis in mammalian cells. II. Isolation and characterization of a mutant of Chinese hamster ovary cells with defective dihydroorotate dehydrogenase (E.C. 1.3.3.1) activity.
    Stamato TD; Patterson D
    J Cell Physiol; 1979 Mar; 98(3):459-68. PubMed ID: 220270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
    Pizzorno G; Wiegand RA; Lentz SK; Handschumacher RE
    Cancer Res; 1992 Apr; 52(7):1660-5. PubMed ID: 1551097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium.
    Pitts WJ; Jetter JW; Pinto DJ; Orwat MJ; Batt DG; Sherk SR; Petraitis JJ; Jacobson IC; Copeland RA; Dowling RL; Jaffee BD; Gardner TL; Jones EA; Magolda RL
    Bioorg Med Chem Lett; 1998 Feb; 8(3):307-12. PubMed ID: 9871675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.